This segment focuses on the discovery and development of oral antiviral therapies to combat a range of infectious diseases. Key research and development activities include preclinical studies, Phase 1, 2, and 3 clinical trials, and regulatory submissions for drug approvals. The segment leverages advanced virology, molecular biology, and medicinal chemistry techniques to identify and optimize novel antiviral drug candidates. Therapeutic areas of focus include COVID-19, hepatitis C virus (HCV), dengue fever, and other RNA viral infections. The goal is to improve patient outcomes by providing effective, convenient, and accessible oral antiviral treatments. Market positioning involves competing with existing antiviral therapies and developing innovative solutions to address unmet medical needs. Future opportunities include expanding the pipeline with new antiviral drug candidates and exploring combination therapies to enhance efficacy and prevent resistance. Regulatory and clinical aspects are critical, with a focus on meeting stringent FDA and EMA requirements for drug safety and efficacy. Partnerships and collaborations with academic institutions, research organizations, and pharmaceutical companies are essential for advancing research and development efforts.